GGM Wealth Advisors’s Tarsus Pharmaceuticals TARS Stock Holding History

GGM Wealth Advisors’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$654K	Sell	13,156 -26,143	-67%	-$1.29M	0.36%	59
2024 Q4	$2.18M	Sell	39,299 -14,331	-27%	-$651K	1.14%	27
2024 Q3	$1.76M	Buy	53,630 +30	+0.1%	+$843	0.76%	34
2024 Q2	$1.46M	Sell	53,600 -10	-0%	-$336	0.67%	37
2024 Q1	$1.94M	Hold	53,610	–	–	0.91%	28
2023 Q4	$1.38M	Hold	53,610	–	–	0.57%	42
2023 Q3	$953K	Sell	53,610 -15	-0%	-$265	0.41%	48
2023 Q2	$939K	Buy	+53,625	New	+$853K	0.38%	48

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

GGM Wealth Advisors's TARS Position: Q1 2025 in Review

GGM Wealth Advisors reduced its Tarsus Pharmaceuticals (TARS) stake by 67% in Q1 2025, selling an estimated $1.29M and leaving 13,156 shares worth $654K. The position accounts for 0.36% of the portfolio, ranked #59.

GGM Wealth Advisors first reported a position in TARS in Q2 2023 and has held it in 8 quarters since. The position peaked at $2.18M in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

GGM Wealth Advisors held 13,156 shares of Tarsus Pharmaceuticals worth $654K as of Q1 2025.
GGM Wealth Advisors sold 26,143 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $1.29M.
Tarsus Pharmaceuticals made up 0.36% of GGM Wealth Advisors's portfolio in Q1 2025, its #59 holding.
GGM Wealth Advisors first reported a position in Tarsus Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
GGM Wealth Advisors's Tarsus Pharmaceuticals position peaked at $2.18M in Q4 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on GGM Wealth Advisors's 13F filing for Q1 2025, filed 1 May 2025.